Correlation of Immune-Related Adverse Events and Effects of Pembrolizumab Monotherapy in Patients with Non-Small Cell Lung Cancer

Susumu Noguchi, Keiichiro Suminaga, Takahiro Kaki, Hiroaki Kawachi, Akari Fukao, Satoshi Terashita, Sadao Horikawa, Tatsuyoshi Ikeue, Takakazu Sugita Respiratory Medicine, Japanese Red Cross Wakayama Medical Center, Wakayama, JapanCorrespondence: Susumu NoguchiRespiratory Medicine, Japanese Red Cros...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Noguchi S, Suminaga K, Kaki T, Kawachi H, Fukao A, Terashita S, Horikawa S, Ikeue T, Sugita T
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	lung cancer pembrolizumab adverse drug event correlation study Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/cbc0ca4b6de84f08807ba3c3cbe82a7f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:cbc0ca4b6de84f08807ba3c3cbe82a7f
record_format	dspace
spelling	oai:doaj.org-article:cbc0ca4b6de84f08807ba3c3cbe82a7f2021-12-02T12:13:09ZCorrelation of Immune-Related Adverse Events and Effects of Pembrolizumab Monotherapy in Patients with Non-Small Cell Lung Cancer1179-2728https://doaj.org/article/cbc0ca4b6de84f08807ba3c3cbe82a7f2020-07-01T00:00:00Zhttps://www.dovepress.com/correlation-of-immune-related-adverse-events-and-effects-of-pembrolizu-peer-reviewed-article-LCTThttps://doaj.org/toc/1179-2728Susumu Noguchi, Keiichiro Suminaga, Takahiro Kaki, Hiroaki Kawachi, Akari Fukao, Satoshi Terashita, Sadao Horikawa, Tatsuyoshi Ikeue, Takakazu Sugita Respiratory Medicine, Japanese Red Cross Wakayama Medical Center, Wakayama, JapanCorrespondence: Susumu NoguchiRespiratory Medicine, Japanese Red Cross Wakayama Medical Center, 20-4, Komatsubara Street, Wakayama City 640-8558, JapanTel +81-73-422-4171Fax +81-73-426-1168Email snoguchi515@gmail.comPurpose: The effects of immune checkpoint inhibitors have been reported to be linked with immune-related adverse events (irAEs). In patients with advanced non-small-cell lung cancer, who tested positive for programmed death-ligand 1 (PD-L1), pembrolizumab, an immune checkpoint inhibitor can be used as a treatment, and it was found to improve overall survival. However, there are only a few reports on the relationship between the therapeutic effects of pembrolizumab in patients with lung cancer and the irAEs of pembrolizumab. The purpose of this study was to determine the correlation between immune-related adverse events and the effects of pembrolizumab monotherapy in patients with non-small-cell lung cancer.Patients and Methods: From February 2017 to August 2019, we conducted a retrospective analysis of the effects of pembrolizumab treatment and immune-related adverse events in 94 patients with non-small-cell lung cancer treated with pembrolizumab only.Results: In 63 cases, irAEs were observed. The most common irAE was rash. PD-L1 positivity ≥ 50% tended to cause irAEs. The median progression-free survival (PFS) rates with and without irAEs were 371 days (95% CI, 184-NR) and 67 days (95% CI, 51– 87 days), respectively. In a multivariate analysis, irAEs and Eastern Cooperative Oncology Group performance status (PS) were the factors related to PFS.Conclusion: In patients with lung cancer, who were treated with pembrolizumab monotherapy, the development of irAEs was likely indicative of the positive effects of pembrolizumab. This novel finding appears to be useful for clinicians who work with pembrolizumab for lung cancer treatment.Keywords: lung cancer, pembrolizumab, adverse drug event, correlation studyNoguchi SSuminaga KKaki TKawachi HFukao ATerashita SHorikawa SIkeue TSugita TDove Medical Pressarticlelung cancerpembrolizumabadverse drug eventcorrelation studyNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENLung Cancer: Targets and Therapy, Vol Volume 11, Pp 53-57 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	lung cancer pembrolizumab adverse drug event correlation study Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	lung cancer pembrolizumab adverse drug event correlation study Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Noguchi S Suminaga K Kaki T Kawachi H Fukao A Terashita S Horikawa S Ikeue T Sugita T Correlation of Immune-Related Adverse Events and Effects of Pembrolizumab Monotherapy in Patients with Non-Small Cell Lung Cancer
description	Susumu Noguchi, Keiichiro Suminaga, Takahiro Kaki, Hiroaki Kawachi, Akari Fukao, Satoshi Terashita, Sadao Horikawa, Tatsuyoshi Ikeue, Takakazu Sugita Respiratory Medicine, Japanese Red Cross Wakayama Medical Center, Wakayama, JapanCorrespondence: Susumu NoguchiRespiratory Medicine, Japanese Red Cross Wakayama Medical Center, 20-4, Komatsubara Street, Wakayama City 640-8558, JapanTel +81-73-422-4171Fax +81-73-426-1168Email snoguchi515@gmail.comPurpose: The effects of immune checkpoint inhibitors have been reported to be linked with immune-related adverse events (irAEs). In patients with advanced non-small-cell lung cancer, who tested positive for programmed death-ligand 1 (PD-L1), pembrolizumab, an immune checkpoint inhibitor can be used as a treatment, and it was found to improve overall survival. However, there are only a few reports on the relationship between the therapeutic effects of pembrolizumab in patients with lung cancer and the irAEs of pembrolizumab. The purpose of this study was to determine the correlation between immune-related adverse events and the effects of pembrolizumab monotherapy in patients with non-small-cell lung cancer.Patients and Methods: From February 2017 to August 2019, we conducted a retrospective analysis of the effects of pembrolizumab treatment and immune-related adverse events in 94 patients with non-small-cell lung cancer treated with pembrolizumab only.Results: In 63 cases, irAEs were observed. The most common irAE was rash. PD-L1 positivity ≥ 50% tended to cause irAEs. The median progression-free survival (PFS) rates with and without irAEs were 371 days (95% CI, 184-NR) and 67 days (95% CI, 51– 87 days), respectively. In a multivariate analysis, irAEs and Eastern Cooperative Oncology Group performance status (PS) were the factors related to PFS.Conclusion: In patients with lung cancer, who were treated with pembrolizumab monotherapy, the development of irAEs was likely indicative of the positive effects of pembrolizumab. This novel finding appears to be useful for clinicians who work with pembrolizumab for lung cancer treatment.Keywords: lung cancer, pembrolizumab, adverse drug event, correlation study
format	article
author	Noguchi S Suminaga K Kaki T Kawachi H Fukao A Terashita S Horikawa S Ikeue T Sugita T
author_facet	Noguchi S Suminaga K Kaki T Kawachi H Fukao A Terashita S Horikawa S Ikeue T Sugita T
author_sort	Noguchi S
title	Correlation of Immune-Related Adverse Events and Effects of Pembrolizumab Monotherapy in Patients with Non-Small Cell Lung Cancer
title_short	Correlation of Immune-Related Adverse Events and Effects of Pembrolizumab Monotherapy in Patients with Non-Small Cell Lung Cancer
title_full	Correlation of Immune-Related Adverse Events and Effects of Pembrolizumab Monotherapy in Patients with Non-Small Cell Lung Cancer
title_fullStr	Correlation of Immune-Related Adverse Events and Effects of Pembrolizumab Monotherapy in Patients with Non-Small Cell Lung Cancer
title_full_unstemmed	Correlation of Immune-Related Adverse Events and Effects of Pembrolizumab Monotherapy in Patients with Non-Small Cell Lung Cancer
title_sort	correlation of immune-related adverse events and effects of pembrolizumab monotherapy in patients with non-small cell lung cancer
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/cbc0ca4b6de84f08807ba3c3cbe82a7f
work_keys_str_mv	AT noguchis correlationofimmunerelatedadverseeventsandeffectsofpembrolizumabmonotherapyinpatientswithnonsmallcelllungcancer AT suminagak correlationofimmunerelatedadverseeventsandeffectsofpembrolizumabmonotherapyinpatientswithnonsmallcelllungcancer AT kakit correlationofimmunerelatedadverseeventsandeffectsofpembrolizumabmonotherapyinpatientswithnonsmallcelllungcancer AT kawachih correlationofimmunerelatedadverseeventsandeffectsofpembrolizumabmonotherapyinpatientswithnonsmallcelllungcancer AT fukaoa correlationofimmunerelatedadverseeventsandeffectsofpembrolizumabmonotherapyinpatientswithnonsmallcelllungcancer AT terashitas correlationofimmunerelatedadverseeventsandeffectsofpembrolizumabmonotherapyinpatientswithnonsmallcelllungcancer AT horikawas correlationofimmunerelatedadverseeventsandeffectsofpembrolizumabmonotherapyinpatientswithnonsmallcelllungcancer AT ikeuet correlationofimmunerelatedadverseeventsandeffectsofpembrolizumabmonotherapyinpatientswithnonsmallcelllungcancer AT sugitat correlationofimmunerelatedadverseeventsandeffectsofpembrolizumabmonotherapyinpatientswithnonsmallcelllungcancer
_version_	1718394600456978432

Correlation of Immune-Related Adverse Events and Effects of Pembrolizumab Monotherapy in Patients with Non-Small Cell Lung Cancer

Ejemplares similares